Blincyto Receives Conditional Approval from Health Canada

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Health Canada granted conditional approval of Blincyto (blinatumomab) for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B precursor acute lymphoblastic leukemia.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login